Marisym Biologicals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 13-12-2024
- Paid Up Capital ₹ 2.00 Cr
as on 13-12-2024
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 6.90 Cr
as on 13-12-2024
- Satisfied Charges ₹ 9.30 Cr
as on 13-12-2024
- Revenue -99.83%
(FY 2023)
- Profit -99.87%
(FY 2023)
- Ebitda -99.83%
(FY 2023)
- Net Worth -99.85%
(FY 2023)
- Total Assets -99.83%
(FY 2023)
About Marisym Biologicals
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹6.90 Cr. The company has closed loans amounting to ₹9.30 Cr, as per Ministry of Corporate Affairs (MCA) records.
Kokila Marimuthu, Preethi Marimuthu, Praveen Marimuthu, and One other member serve as directors at the Company.
- CIN/LLPIN
U01100TZ2019PTC031572
- Company No.
031572
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Jan 2019
- Date of AGM
28 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Coimbatore, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Marisym Biologicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Praveen Marimuthu  | Managing Director | 21-Jan-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Preethi Marimuthu | Director | 21-Jan-2019 | Current |
| Kokila Marimuthu | Director | 21-Jan-2019 | Current |
| Kuppusamy Arularasan | Director | 11-Mar-2023 | Current |
Financial Performance of Marisym Biologicals.
Marisym Biologicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 99.83% decrease. The company also saw a substantial fall in profitability, with a 99.87% decrease in profit. The company's net worth observed a substantial decline by a decrease of 99.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Marisym Biologicals?
Unlock access to Marisym Biologicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Ponni Symbiologicals Private LimitedActive 5 years 11 monthsKokila Marimuthu, Preethi Marimuthu and 1 more are mutual person
Tropical Biosciences Private LimitedActive 10 years 6 monthsKokila Marimuthu and Preethi Marimuthu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 31 Aug 2024 | ₹6.90 Cr | Open |
Canara Bank Creation Date: 18 Jul 2020 | ₹9.30 Cr | Satisfied |
How Many Employees Work at Marisym Biologicals?
Marisym Biologicals has a workforce of 47 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Marisym Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Marisym Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
